PURPOSE: To assess the benefit of breast surgery for inflammatory breast cancer (IBC). METHODS AND MATERIALS: This retrospective series was based on 232 patients treated for IBC. All patients received primary chemotherapy followed by either exclusive radiotherapy (118 patients; 51%) or surgery with or without radiotherapy (114 patients; 49%). The median follow-up was 11 years. RESULTS: The two groups were comparable apart from fewer tumors <70 mm (43% vs. 33%, p = 0.003), a higher rate of clinical stage N2 (15% vs. 5%, p = 0.04), and fewer histopathologic Grade 3 tumors (46% vs. 61%, p <0.05) in the no-surgery group. The addition of surgery was associated with a significant improvement in locoregional disease control (p = 0.04) at 10 years locoregional free interval 78% vs. 59% but with no significant difference in overall survival rates or disease-free intervals. Late toxicities were not significantly different between the two treatment groups except for a higher rate of fibrosis in the no-surgery group (p <0.0001) and more lymphedema in the surgery group (p = 0.002). CONCLUSION: Our data suggest an improvement in locoregional control in patients treated by surgery, in conjunction with chemotherapy and radiotherapy, for IBC. Efforts must be made to improve overall survival.
PURPOSE: To assess the benefit of breast surgery for inflammatory breast cancer (IBC). METHODS AND MATERIALS: This retrospective series was based on 232 patients treated for IBC. All patients received primary chemotherapy followed by either exclusive radiotherapy (118 patients; 51%) or surgery with or without radiotherapy (114 patients; 49%). The median follow-up was 11 years. RESULTS: The two groups were comparable apart from fewer tumors <70 mm (43% vs. 33%, p = 0.003), a higher rate of clinical stage N2 (15% vs. 5%, p = 0.04), and fewer histopathologic Grade 3 tumors (46% vs. 61%, p <0.05) in the no-surgery group. The addition of surgery was associated with a significant improvement in locoregional disease control (p = 0.04) at 10 years locoregional free interval 78% vs. 59% but with no significant difference in overall survival rates or disease-free intervals. Late toxicities were not significantly different between the two treatment groups except for a higher rate of fibrosis in the no-surgery group (p <0.0001) and more lymphedema in the surgery group (p = 0.002). CONCLUSION: Our data suggest an improvement in locoregional control in patients treated by surgery, in conjunction with chemotherapy and radiotherapy, for IBC. Efforts must be made to improve overall survival.
Authors: Prasanta Das; Ann O Omollo; Lungile J Sitole; Eric McClendon; Edward J Valente; Drazen Raucher; Leslie R Walker; Ashton T Hamme Journal: Tetrahedron Lett Date: 2015-04-01 Impact factor: 2.415
Authors: Catherine L Akay; Naoto T Ueno; Gary B Chisholm; Gabriel N Hortobagyi; Wendy A Woodward; Ricardo H Alvarez; Isabelle Bedrosian; Henry M Kuerer; Kelly K Hunt; Lei Huo; Gildy V Babiera Journal: Cancer Date: 2014-02-07 Impact factor: 6.860
Authors: Tithi Biswas; Charulata Jindal; Timothy L Fitzgerald; Jimmy T Efird Journal: Int J Environ Res Public Health Date: 2019-01-04 Impact factor: 3.390